Pharmaceutical companies agree to significant Medicare drug price cuts under Trump administration, projecting billions in savings with impacts on Medicare Part D and drug affordability.
CMS unveils the GENERous Medicaid payment model introducing MFN drug pricing, alongside expanded Trump administration drug pricing agreements and key regulatory updates for 2026.
Novo Nordisk and Eli Lilly agree to lower GLP-1 drug prices in exchange for expanded Medicare and Medicaid coverage, marking a major shift in U.S. drug pricing and access.
The looming deadline for drugmakers to comply with the Most Favored Nation drug pricing policy raises concerns over potential disruptions to Medicare Part D, highlighting regulatory and market risks for U.S. drug pricing and federal entitlement programs.
Analysis finds GLP-1 drugs like semaglutide offer real health benefits but raise insurance coverage and cost challenges amid growing demand in the U.S. market.
FTC cautions healthcare employers on noncompetes. Rising physician unionization, Medicare Plan Finder updates, Kaiser-Renown joint venture, AI tools, FDA drug approvals, and robotic intubation device mark key healthcare industry trends in 2025.
Delaware Department of Insurance analysis finds GLP-1 drug prices effectively stable after rebates, indicating limited impact on health insurance cost increases despite higher utilization.
Trump administration proposes a Medicare and Medicaid pilot to cover GLP-1 weight loss drugs, highlighting access benefits alongside fraud and regulatory oversight challenges.
CMS plans a voluntary five-year trial allowing state Medicaid and Medicare Part D plans to cover GLP-1 weight management drugs, including Ozempic and Wegovy, starting in 2026-27 amid pricing and coverage challenges.
Medicare faces evolving opportunities and challenges in covering weight loss drugs through legislation like the Treat and Reduce Obesity Act and federal demonstration projects. Drug adherence and cost-effectiveness remain key issues.
